Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)

DOI: 10.1007/s00277-014-2224-8
Annals of Hematology, 2014, 93, 1953-63.

#	Paper	IF	Citations
61	Pathophysiology of Trousseau's syndrome. *Hamostaseologie*, **2015**, 35, 52-9	1.9	14
60	[Haemostatic aspects in clinical oncology]. *Hamostaseologie*, **2015**, 35, 152-64; quiz 165	1.9	5
59	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 715-27	2	4
58	Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment. *Hamostaseologie*, **2016**, 36, 241-260	1.9	6
57	Do we need antiplatelet therapy in thrombocytosis? Pro. Diagnostic and pathophysiologic considerations for a treatment choice. *Hamostaseologie*, **2016**, 36, 227-240	1.9	5
56	Heparanase procoagulant activity in cancer progression. *Thrombosis Research*, **2016**, 140 Suppl 1, S44-8	8.2	27
55	Venous thromboembolism in cancer patients: risk assessment, prevention and management. *Future Cardiology*, **2016**, 12, 221-35	1.3	2
54	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. *Leukemia*, **2016**, 30, 2032-2038	10.7	55
53	JAK-2 V617F mutation increases heparanase procoagulant activity. *Thrombosis and Haemostasis*, **2016**, 115, 73-80	7	21
52	Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. *Journal of Hematology and Oncology*, **2016**, 9, 18	22.4	95
51	Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). *Annals of Hematology*, **2016**, 95, 707-18	3	26
50	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. *Leukemia and Lymphoma*, **2017**, 58, 2786-2798	1.9	12
49	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. *Blood*, **2017**, 129, 3285-3293	2.2	27
48	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. *Haematologica*, **2017**, 102, 18-29	6.6	8
47	Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. *Therapeutic Advances in Hematology*, **2017**, 8, 107-118	5.7	23
46	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. *British Journal of Haematology*, **2017**, 176, 352-364	4.5	19
45	Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?. *Cerebrovascular Diseases*, **2017**, 44, 97-104	3.2	11

44	An Overview of Thrombophilia and Associated Laboratory Testing. *Methods in Molecular Biology*, **2017**, 1646, 113-135	1.4	21
43	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. *BioMed Research International*, **2017**, 2017, 9876819	3	5
42	Complications and management of coagulation disorders in leukemia patients. *Blood and Lymphatic Cancer: Targets and Therapy*, **2017**, 7, 61-72	2.6	6
41	Pathophysiology of Trousseau syndrome. *Phlebologie*, **2018**, 47, 24-31	0.3	
40	Oral Anticoagulation for Primary Prophylaxis of Venous Thromboembolism in Patients with Cancer. *American Journal of Medicine*, **2018**, 131, 902-907	2.4	
39	Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms. *Current Hematologic Malignancy Reports*, **2018**, 13, 183-190	4.4	6
38	Current approaches to challenging scenarios in myeloproliferative neoplasms. *Expert Review of Anticancer Therapy*, **2018**, 18, 567-578	3.5	3
37	The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. *Experimental Hematology and Oncology*, **2018**, 7, 31	7.8	5
36	Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source. *Journal of Stroke and Cerebrovascular Diseases*, **2018**, 27, 2572-2578	2.8	4
35	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. *Blood Cancer Journal*, **2019**, 9, 61	7	17
34	Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. *TH Open*, **2019**, 3, e203-e209	2.7	3
33	Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. *Journal of Thrombosis and Thrombolysis*, **2019**, 48, 141-148	5.1	2
32	Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants. *Clinical and Applied Thrombosis/Hemostasis*, **2019**, 25, 1076029619846562	3.3	3
31	Head injury in the elderly - an overview for the physician. *Clinical Medicine*, **2019**, 19, 177-184	1.9	5
30	Acute ischemic stroke in myeloproliferative neoplasia: Using molecular pathophysiology knowledge to treat prothrombotic state with direct oral anticoagulants. *Neurology and Clinical Neuroscience*, **2019**, 7, 85-87	0.3	2
29	A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2 trial. *British Journal of Haematology*, **2019**, 185, 691-700	4.5	3
28	Developments in diagnosis and treatment of essential thrombocythemia. *Expert Review of Hematology*, **2019**, 12, 159-171	2.8	4
27	High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. *Annals of Hematology*, **2019**, 98, 93-100	3	20

26	Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group. *Acta Haematologica*, **2021**, 144, 438-445	2.7	
25	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. *Cancers*, **2020**, 12,	6.6	9
24	Esssential thrombocythaemia and pregnancy-A need for prospective study and a consensus on its management. *Leukemia Research*, **2021**, 102, 106500	2.7	1
23	Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. *Medical Principles and Practice*, **2021**, 30, 412-421	2.1	1
22	Myeloproliferative Neoplasien (MPN) Update 2020. *Tumor Diagnostik Und Therapie*, **2021**, 42, 185-192	0.1	
21	Anticoagulation for Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: The Drug and the Duration. *Hemato*, **2021**, 2, 255-263	0.2	0
20	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. *Hemato*, **2021**, 2, 305-328	0.2	1
19	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). *Cancers*, **2021**, 13,	6.6	2
18	The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms. *Hemato*, **2021**, 2, 392-402	0.2	
17	Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. *Haematologica*, **2021**,	6.6	2
16	Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. *Cancers*, **2021**, 13,	6.6	2
15	Thrombocytosis and thrombosis. *Japanese Journal of Thrombosis and Hemostasis*, **2021**, 32, 383-388	0	
14	Malignant Cerebral Venous Sinus Thrombosis in Polycythemia. *Journal of Stroke*, **2015**, 17, 362-5	5.6	1
13	Atypical venous thromboses in myeloproliferative neoplasias. *Phlebologie*, **2015**, 44, 324-329	0.3	
12	Platelets in Deep Venous Thrombosis and Pulmonary Embolism. **2017**, 1043-1051		
11	Genetic Markers of Hereditary Thrombophilia and Risk of Thrombotic Complications in Patients with Polycythemia Vera. *Klinicheskaya Onkogematologiya/Clinical Oncohematology*, **2017**, 10, 85-92	0.3	1
10	Recurrent cerebral venous sinus thrombosis in a young man- A case report of -negative polycythemia vera. *Journal of Family Medicine and Primary Care*, **2019**, 8, 3422-3424	1.5	
9	Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome. **2019**, 3, 053-059		

8	The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. *Plasmatology*, **2020**, 13, 2634853520978210	1.8	5
7	Myeloproliferative Neoplasien (MPN). *Klinikarzt*, **2020**, 49, 502-509	0	1
6	Atypical Site of Venous Thrombosis Despite Appropriate Anticoagulation in a Patient with Myeloproliferative Neoplasm. *Medica*, **2020**, 15, 532-535		
5	Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms.. *Journal of Personalized Medicine*, **2022**, 12,	3.6	1
4	Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1
3	Advancing Our Clinical Perspectives in Haematology: What Is Your Approach?. 2-9		0
2	Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms. 1-20		0
1	Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms. 1-9		0